Agilon Health (AGL) AI Stock Analysis

• Market Cap: $330.09M
• Dividend Yield: N/A
• Average Volume (3M): 6.57M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: 10.12%
• EPS Growth: -29.12%
• Country: US
• Employees: 1,076
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 414,423,160
• 10 Day Avg. Volume: 6,567,341
• 30 Day Avg. Volume: 6,570,537
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.02
• Enterprise Value/Revenue: 0.11
• Enterprise Value/Gross Profit: -6.02
• Enterprise Value/Ebitda: -2.24
• 1Y Price Target: $1.23
• Price Target Upside: 53.75% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 16

• Rating: 42 Neutral
• Price Target: $1.00 ▲(25.00% Upside)

Agilon Health's overall stock score reflects significant financial and operational challenges. The most significant factor is the company's poor financial performance, characterized by declining revenues and negative profitability metrics. Technical analysis indicates bearish momentum, and valuation metrics are unattractive with a negative P/E ratio. While the earnings call outlined strategic initiatives, the withdrawal of 2025 guidance and disappointing financial results weigh heavily on the outlook.

Positive Factors

Strong Quality and Clinical Outcomes

Agilon Health's superior quality metrics indicate strong operational capabilities and a competitive advantage in healthcare delivery, which can enhance patient satisfaction and drive long-term partnerships with providers and payers.

Reduction in Part D Exposure

Reducing exposure to Medicare Part D risk helps Agilon Health stabilize its financial performance by minimizing variability in revenue streams, allowing for more predictable financial outcomes and strategic planning.

Enhanced Data Platform

Improved data visibility and timeliness through an enhanced platform strengthens Agilon Health's ability to manage care effectively, optimize operations, and support value-based care initiatives, driving long-term efficiency and effectiveness.

Negative Factors

Disappointing Financial Results

Declining revenue and negative medical margins highlight operational inefficiencies and financial challenges, which could hinder Agilon Health's ability to invest in growth and maintain competitive positioning.

Withdrew 2025 Guidance

Withdrawing guidance reflects uncertainty and potential instability in Agilon Health's strategic direction, which may affect investor confidence and the company's ability to execute long-term plans effectively.

Lower-than-Expected Risk Adjustment

Lower-than-expected risk adjustments can negatively impact Agilon Health's revenue and profitability, posing a challenge to financial stability and necessitating adjustments in operational strategies to mitigate revenue shortfalls.

Agilon Health Business Overview & Revenue Model

Company Description

Agilon Health (AGL) is a healthcare technology and services company focused on transforming the delivery of care for seniors. It operates within the healthcare sector, providing value-based care solutions that empower primary care physicians and enhance patient outcomes. Agilon Health partners with healthcare providers and payers to deliver integrated care management services, leveraging data analytics and technology to streamline operations and improve care coordination for Medicare Advantage plans.

How the Company Makes Money

Agilon Health generates revenue primarily through its partnerships with Medicare Advantage plans and healthcare providers. The company operates on a value-based care model, receiving payments based on the quality and efficiency of care delivered rather than the volume of services provided. Key revenue streams include care management fees, shared savings from improved patient outcomes, and risk-sharing agreements with payers. Agilon also benefits from technology platform subscriptions and analytics services that enhance the operations of its partner healthcare providers, creating a sustainable and scalable business model focused on improving senior healthcare.

Agilon Health Financial Statement Overview

Summary

Agilon Health faces significant financial challenges, marked by ongoing losses and cash flow issues. While revenue growth has been strong, the company struggles with profitability, leading to a negative impact on equity and cash positions. The low leverage provides some financial flexibility, but improving margins and cash generation is critical for future stability.

Income Statement

Agilon Health's income statement reveals significant challenges with profitability and growth. The TTM shows a gross profit margin of -0.53%, indicating costs exceed revenues. The net profit margin is -4.04%, reflecting ongoing losses. Revenue growth has been robust historically, with a compound annual growth rate of approximately 32% from 2020 to 2025 TTM, yet profitability remains elusive with negative EBIT and EBITDA margins in the TTM.

Balance Sheet

The balance sheet shows a moderate financial position. The debt-to-equity ratio of 0.08 in the TTM suggests low leverage, which is positive. However, the return on equity is negative due to consistent net losses, and the equity ratio has decreased from 66% in 2021 to 26% in the TTM, indicating growing liabilities and reduced equity.

Cash Flow

The cash flow analysis indicates weak cash generation. The operating cash flow to net income ratio is positive, suggesting some ability to convert income into cash, but free cash flow remains negative and volatile. The free cash flow to net income ratio shows a consistent pattern of cash outflows exceeding net income losses, reflecting ongoing cash challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.90B	6.06B	4.32B	2.71B	1.83B	1.22B
Gross Profit	-110.62M	4.84M	69.67M	112.29M	76.41M	94.15M
EBITDA	-297.75M	-218.19M	-167.64M	-72.41M	-383.78M	-40.11M
Net Income	-315.66M	-260.15M	-262.60M	-106.86M	-405.48M	-63.21M
Balance Sheet
Total Assets	1.71B	1.73B	1.74B	1.70B	1.59B	446.36M
Cash, Cash Equivalents and Short-Term Investments	327.00M	399.97M	488.34M	908.97M	1.04B	106.80M
Total Debt	41.37M	41.50M	52.31M	43.48M	48.40M	73.21M
Total Liabilities	1.30B	1.26B	1.08B	656.86M	494.66M	731.09M
Stockholders Equity	408.93M	470.95M	661.84M	1.04B	1.09B	-284.73M
Cash Flow
Free Cash Flow	-70.55M	-71.03M	-187.01M	-163.47M	-161.59M	-55.55M
Operating Cash Flow	-58.36M	-57.78M	-156.20M	-130.81M	-148.16M	-53.20M
Investing Cash Flow	117.61M	139.89M	-44.02M	-444.39M	-90.51M	22.07M
Financing Cash Flow	-4.17M	-2.58M	-193.13M	28.06M	1.15B	24.62M

Agilon Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGL, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 0.96, below the 50-day MA of 1.08, and below the 200-day MA of 2.53, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 31.69 is Neutral, neither overbought nor oversold. The STOCH value of 7.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AGL.

Agilon Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMN	―	$754.60M	―	-40.13%	―	-14.33%	-398.68%
BTMD	―	$141.89M	3.18	―	―	6.32%	344.42%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INNV	―	$714.81M	-23.54	-12.02%	―	11.76%	-42.52%
CCRN	―	$401.64M	-47.35	-1.96%	―	-24.30%	-210.27%
PIII	―	$63.54M	-0.18	-138.17%	―	4.20%	-54.16%
AGL	―	$330.09M	―	-60.64%	―	10.12%	-29.12%

Agilon Health Corporate Events

Agilon Health’s Earnings Call: Challenges and Optimism

Agilon Health Faces Challenging Quarter Amid Leadership Changes and Financial Struggles

Agilon Health Reports Q2 2025 Results Amid Leadership Change

Agilon Health Inc. is a company that partners with physicians to transform healthcare through a value-based Total Care Model, focusing on senior patients across the United States. The company operates in the healthcare sector, providing technology, capital, and a network to support independent physician practices.

Agilon Health CEO Resignation and Earnings Guidance Suspension

On July 29, 2025, Steven J. Sell resigned as CEO and President of Agilon Health, leading to the establishment of an Office of the Chairman and interim executive officers. This leadership change, along with market challenges, prompted Agilon to suspend its 2025 earnings guidance. The company’s second-quarter results showed a 6% revenue decline and significant losses, attributed to market exits and reduced risk adjustment revenue. Agilon continues to focus on strategic initiatives to improve performance and expects to benefit from these efforts in the future.

The most recent analyst rating on (AGL) stock is a Sell with a $2.40 price target. To see the full list of analyst forecasts on Agilon Health stock, see the AGL Stock Forecast page.